Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib, Dalpiciclib, and Endocrine Therapy in HR+/HER2+ Advanced Breast Cancer
NCT03772353Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- May 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Fudan University. Primary endpoints: Adverse Events at 2 years and Objective Response Rate at 12 months. Started May 2019; status: active, not recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03772353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03772353.